纳斯达克 · USD

Silexion Therapeutics Corp (SLXNW) 股票分析

Silexion Therapeutics Corp（SLXNW）是在纳斯达克上市的股票，以美元交易。

SLXNW

$0.01

+$0.00 (+23.89%)

2026年9月2日 · 收盘

这是一只衍生品——Silexion Therapeutics Corp（SLXN）普通股的认股权证。

发行人的基本面数据显示在发行人页面，而非本页。

查看SLXN →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

SLXNW 关键统计数据

数据截至2026年9月2日

交易

开盘价: $0.03
前收盘价: $0.01
Beta系数: −0.27

仅显示公司披露的指标。数据由Yahoo Finance通过yfinance提供。每日更新。

SLXNW 历年回报率

历年回报率根据每日收盘价计算。不完整年度以浅色显示并标有星号。

年份	回报率
2026 (不完整年度)	−44.66%
2025 (不完整年度)	+0.00%

数据截至2026年9月2日。

关于Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

公司简介以英文显示。

访问官网 →